Clinical Study

Ucci-Hem-17-01- Feasibility And Safety Of Intrathecal Rituximab Added To Standard Intrathecal Prophylaxis To Prevent Cns Relapse For Cd 20 Positive Non Hodgkin Lymphoma

Posted Date: Jun 11, 2019

  • Investigator: Tahir Latif
  • Specialties: Cancer, Lymphoma, Oncology
  • Type of Study: Drug

The goal of this study is to determine the feasibility and safety of adding intrathecal rituximab to Central Nervous System (CNS) prophylaxis with intrathecal methotrexate for Diffuse Large B cell Lymphoma patients considered at high-risk of Central nervous system relapse.


To Be Eligible: Patients Must Be 18 Years Of Age Or Older, No Uncontrolled Infection Or Active Malignancy, Must Be Nonpregnant.


Non-Hodgkin Lymphoma, Lymphoma

For More Information:

Ucci Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.